Form 4: Neurocrine Biosciences Executive Eric Benevich Reports Stock Transactions

Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences, reports the acquisition and disposition of common stock and derivative securities, including transactions made under a Rule 10b5-1 trading plan.

Summary

• On February 28, 2024, Eric Benevich, the Chief Commercial Officer of Neurocrine Biosciences, executed multiple transactions involving the company's stock.
• Benevich acquired 53,143 shares of common stock through the exercise of non-qualified stock options at a price of $43.24 per share.
• He also acquired 21,857 shares of common stock through the exercise of non-qualified stock options at a price of $79.02 per share.
• Simultaneously, Benevich disposed of 53,143 shares and 21,857 shares of common stock at a weighted average sales price of $134.6881 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 29, 2023.
• Following these transactions, Benevich directly owns 40,616 shares of Neurocrine Biosciences common stock.
• He also holds 39,360 non-qualified stock options.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information. The use of a 10b5-1 plan suggests a neutral, pre-planned approach to managing stock holdings.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without being accused of trading on non-public information.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• The vesting schedules and expiration dates of these options are typical for the industry.
• The use of a 10b5-1 trading plan is a standard practice for executives to manage their stock sales in a compliant manner.
• Comparing Benevich's transactions to those of executives at similar-sized biotech companies like Biogen or Vertex Pharmaceuticals would provide a benchmark for assessing the scale and frequency of his stock activity.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership.
• The use of a 10b5-1 trading plan ensures transparency and compliance with regulations, which is beneficial for stakeholders.

Key Dates